SARS-CoV-2 Coronavirus (COVID-19)

well, i was on the patio until a few weeks ago

 

While decreasing, daily deaths are still well above the lows between earlier waves, and 4X above the rate of late June and early July:

We've been enjoying the outdoors all along. It was always safer than indoors.

 

https://spotlight.kaiserpermanente.org/covid-toes-not-caused-by-covid/

 

i remember reading about covid toes last year. mostly pediatric, they related it to kawasaki's disease iirc.

 

has this already been posted? very interesting, although most of it is beyond me.
s41586-021-03807-6

 

Researchers Warn Some Covid-19 Vaccines Could Increase Risk Of HIV Infection

 

• The researchers warn of a “cautionary tale” from efforts to create an HIV vaccine over a decade ago, where a promising vaccine candidate actually increased the risk of some men catching the virus.
• The vaccine made use of a modified virus — called adenovirus 5 (Ad5) — as a vector to transport some of HIV’s genetic material into the body.
• Exactly how the vaccine increased the risks of HIV transmission is unknown, but a conference convened by the National Institutes of Health recommended against further use of Ad5 as a vector in HIV vaccines (Dr. Anthony Fauci was lead author of the paper outlining this position.)

​

The most effective is a protease inhibitor having NOTHING to do with the cited source.

Bob Wilson

 

This item is more than a year old. If the theoretical issue it brought up is being realized, there ought to be some followup by now.

Dateline: Oct 20, 2020

"Key Background


Lots of vaccines make use of modified viruses to transport material into the human body. Many make use of a modified adenovirus to do this, a virus which is usually harmless except the ability to cause the common cold. Some of the leading candidates for a Covid-19 vaccine, including those from Johnson & Johnson and AstraZeneca, use adenoviruses as vectors. There is no evidence that those vectors increase the risk of HIV infection.

Crucial Quote


The authors said they went public because Ad5 vaccines for Covid-19 might soon be tested in populations with high HIV prevalence. Lawrence Corey, one of the authors who now co-leads the Covid-19 prevention network in the U.S. that is testing vaccines on behalf of the NIH, told Science that if he were in a sub-Saharan African country, where there’s a high prevalence of HIV, “I don’t see why I would pick an Ad5 vector (vaccine) when there are many other alternative choices.”

 

Not sure if it is (and this could be a nothing burger), but they are actively rolling them out rather quickly :

https://en.wikipedia.org/wiki/Convidecia

https://en.wikipedia.org/wiki/Sputnik_V_COVID-19_vaccine

https://en.wikipedia.org/wiki/ImmunityBio

 

None of those are approved in the U.S.

Two are approved in only a single E.U. country, a former member of the Soviet block.

The third hasn't reached Phase III trials anywhere, let alone any approvals.

As far as the U.S. vaxx controversies are concerned, that list has not yet risen above 'nothingburger' status

 

Always amazed at how many westerners think the world revolves around them, or their country.

 

Good thing it is only ‘Westerners’. The rest of the Earth’s population is so magnanimous.

Bob Wilson

 

Always amazed at how many folks bring non-U.S. factors into a primarily U.S.-centric flood of scaremongering.

To repeat:

 

bless your heart

 

lol that was pretty good ! :-D

 

face diapers to some:
wearing-masks-single-most-effective-way-to-tackle-covid-study-finds

 

Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection - Physical Chemistry Chemical Physics (RSC Publishing)



The identification of chemical compounds able to bind specific sites of the human/viral proteins involved in the SARS-CoV-2 infection cycle is a prerequisite to design effective antiviral drugs. Here we conduct a molecular dynamics study with the aim to assess the interactions of ivermectin, an antiparasitic drug with broad-spectrum antiviral activity, with the human Angiotensin-Converting Enzyme 2 (ACE2), the viral 3CLpro and PLpro proteases, and the viral SARS Unique Domain (SUD). The drug/target interactions have been characterized in silico by describing the nature of the non-covalent interactions found and by measuring the extent of their time duration along the MD simulation. Results reveal that the ACE2 protein and the ACE2/RBD aggregates form the most persistent interactions with ivermectin, while the binding with the remaining viral proteins is more limited and unspecific.